Trimbow

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Beclometasone дипропионат, формотерола фумарата дигидрат бромид Glycopyrronium

Available from:

Chiesi Farmaceutici S.p.A.

ATC code:

R03AL09

INN (International Name):

beclometasone, formoterol, glycopyrronium bromide

Therapeutic group:

Лекарства за обструктивна заболявания на дихателните пътища,

Therapeutic area:

Белодробна болест, хронична обструктивна болест

Therapeutic indications:

Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. COPDMaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. AsthmaMaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Product summary:

Revision: 7

Authorization status:

упълномощен

Authorization date:

2017-07-17

Patient Information leaflet

                                100
Б. ЛИСТОВКА
101
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
TRIMBOW 87 МИКРОГРАМА/5 МИКРОГРАМА/9
МИКРОГРАМА РАЗТВОР ПОД НАЛЯГАНЕ ЗА
ИНХАЛАЦИЯ
беклометазонов
дипропионат/формотеролов фумарат
дихидрат/гликопирониум
(beclometasone dipropionate/formoterol fumarate
dihydrate/glycopyrronium)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ИЗПОЛЗВАТЕ ТОВА
ЛЕКАРСТВО, ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА
ЗА ВАС ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар или
фармацевт. Това
включва и всички възможни нежелани
реакции, неописани в тази листовка.
Вижте
точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Trimbow и за какво се
използва
2.
Какво трябва да знаете, преди да
използвате Trimbow
3.
Как да използвате Trimbow
4.
Възможни нежелани реакции
5.
Как да съхранявате Trimbow
6.
Съдържание на опаковката и
допълнителна информация
1.
К
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Trimbow 87 микрограма/5 микрограма/9
микрограма разтвор под налягане за
инхалация
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка доставена доза (дозата, която
излиза от мундщука) съдържа 87
микрограма
беклометазонов дипропионат (beclometasone
dipropionate), 5 микрограма формотеролов
фумарат дихидрат (formoterol fumarate dihydrate) и 9
микрограма гликопирониум
(glycopyrronium) (като 11 микрограма
гликопирониев бромид).
Всяка отмерена доза (дозата, която
излиза от вентила) съдържа 100
микрограма беклометазонов
дипропионат, 6 микрограма
формотеролов фумарат дихидрат и 10
микрограма гликопирониум
(като 12,5 микрограма гликопирониев
бромид).
Помощно вещество с известно действие:
Trimbow съдържа 8,856 mg етанол на
впръскване.
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Разтвор под налягане за инхалация
(инхалация под налягане)
Безцветен до жълтеникав течен
разтвор.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Хронична обструктивна белодробна
болест (ХОББ)
Поддържащо лечение при възрастни
пациенти с умерена до тежка ХОББ, при
които не се
постига достатъчен тер
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 01-04-2022
Public Assessment Report Public Assessment Report Spanish 26-02-2021
Patient Information leaflet Patient Information leaflet Czech 01-04-2022
Public Assessment Report Public Assessment Report Czech 26-02-2021
Patient Information leaflet Patient Information leaflet Danish 01-04-2022
Public Assessment Report Public Assessment Report Danish 26-02-2021
Patient Information leaflet Patient Information leaflet German 01-04-2022
Public Assessment Report Public Assessment Report German 26-02-2021
Patient Information leaflet Patient Information leaflet Estonian 01-04-2022
Public Assessment Report Public Assessment Report Estonian 26-02-2021
Patient Information leaflet Patient Information leaflet Greek 01-04-2022
Public Assessment Report Public Assessment Report Greek 26-02-2021
Patient Information leaflet Patient Information leaflet English 01-04-2022
Public Assessment Report Public Assessment Report English 26-02-2021
Patient Information leaflet Patient Information leaflet French 01-04-2022
Public Assessment Report Public Assessment Report French 26-02-2021
Patient Information leaflet Patient Information leaflet Italian 01-04-2022
Public Assessment Report Public Assessment Report Italian 26-02-2021
Patient Information leaflet Patient Information leaflet Latvian 01-04-2022
Public Assessment Report Public Assessment Report Latvian 26-02-2021
Patient Information leaflet Patient Information leaflet Lithuanian 01-04-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-04-2022
Public Assessment Report Public Assessment Report Lithuanian 26-02-2021
Patient Information leaflet Patient Information leaflet Hungarian 01-04-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 01-04-2022
Public Assessment Report Public Assessment Report Hungarian 26-02-2021
Patient Information leaflet Patient Information leaflet Maltese 01-04-2022
Public Assessment Report Public Assessment Report Maltese 26-02-2021
Patient Information leaflet Patient Information leaflet Dutch 01-04-2022
Public Assessment Report Public Assessment Report Dutch 26-02-2021
Patient Information leaflet Patient Information leaflet Polish 01-04-2022
Public Assessment Report Public Assessment Report Polish 26-02-2021
Patient Information leaflet Patient Information leaflet Portuguese 01-04-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 01-04-2022
Public Assessment Report Public Assessment Report Portuguese 26-02-2021
Patient Information leaflet Patient Information leaflet Romanian 01-04-2022
Public Assessment Report Public Assessment Report Romanian 26-02-2021
Patient Information leaflet Patient Information leaflet Slovak 01-04-2022
Public Assessment Report Public Assessment Report Slovak 26-02-2021
Patient Information leaflet Patient Information leaflet Slovenian 01-04-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 01-04-2022
Public Assessment Report Public Assessment Report Slovenian 26-02-2021
Patient Information leaflet Patient Information leaflet Finnish 01-04-2022
Public Assessment Report Public Assessment Report Finnish 26-02-2021
Patient Information leaflet Patient Information leaflet Swedish 01-04-2022
Public Assessment Report Public Assessment Report Swedish 26-02-2021
Patient Information leaflet Patient Information leaflet Norwegian 01-04-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 01-04-2022
Patient Information leaflet Patient Information leaflet Icelandic 01-04-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 01-04-2022
Patient Information leaflet Patient Information leaflet Croatian 01-04-2022
Public Assessment Report Public Assessment Report Croatian 26-02-2021

View documents history